When was the last time you thought about your lungs unless you were short of breath or down with a cold? Most of us take our lungs for granted, but these spongy, hard-working organs do a lot more than ...

BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for ...

Our Bureau, Chennai Wednesday, April 23, 2025, 13:40 Hrs [IST] ...

From El Paso, Texas, to Richmond, Virginia, medical device warehouses are leaking ethylene oxide, a cancer-causing chemical.

Bristol Myers Squibb today announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class II-III ...

In the Phase III ODYSSEY-HCM trial, patients treated with Camzyos for symptomatic non-obstructive hypertrophic cardiomyopathy did not show significant improvements based on Kansas City Cardiomyopathy ...

Late-breaking oral presentation to include full Phase 1b results for TX45 in the Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”) cohortWATERTOWN, Mass., ...

The 39-year-old, best known for playing Buffy the Vampire Slayer's younger sister Dawn Summers was found dead at her home in New York in February.

The capitalist response to the pandemic has exacted a stark toll of mass death and disability, while accelerating social ...

Bristol Myers Squibb today announced that the U.S. Food and Drug Administration (FDA) has updated the U.S. Prescribing Information for CAMZYOS® (mavacamten, 2.5 mg, 5 mg, 10 mg, 15 mg capsules), ...

Both marketed therapies were recently approved with the first one to market being Revuforj, an oral, first-in-class menin inhibitor ... on the results of a Phase 1/2 trial (AUGMENT-101) in which ...

Apollo Hospitals recently launched the fifth edition of its Health of the Nation 2025 report, titled ‘Symptom-Based ...